EUVIMEDEUVIMED entdecken
Crossref

USP22 inhibition potentiates GPC3 chimeric antigen receptor macrophages efficacy in hepatocellular carcinoma by downregulating tumor CD24 expression

Jun Pan, Sheng Pan, Yunguo Lei, Jinze Li, Xinyang Zhong, Lin Tang, Shengjun Xu, Sunbin Ling, Di Lu, Kai Wang, Sha Hao, Li Li und 6 weitere

Cancer Letters · 2026-09 · 655 · 218593

DOI: 10.1016/j.canlet.2026.218593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Jun Pan und 17 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Combined Multi-Organ Transplantation, Institute of Organ Transplantation, Zhejiang University School of Medicine, Hangzhou, 310…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, CD24 Antigen, Liver Neoplasms, Macrophages. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Medical University, Key R&D Plan in Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although immunotherapy-based regimens have improved overall survival for some patients with advanced hepatocellular carcinoma (HCC), many patients ultimately experience disease progression. Macrophages are abundant in the HCC microenvironment and represent promising therapeutic effectors, yet the potential of combining chimeric antigen receptor macrophages (CAR-M) with macrophage checkpoint targeting remains underexplored. Given that glypican-3 (GPC3), a cell-surface heparan sulfate proteoglycan, is highly expressed in HCC, we developed a GPC3-targeted CAR-M system and evaluated its efficacy alone and in combination with USP22 inhibition. USP22, a deubiquitinating enzyme previously linked to tumor CD24 expression, was selected as a combinatorial target to potentially relieve CD24-associated phagocytic suppression. In vitro assays demonstrated that GPC3 CAR-M cells exhibited specific binding, phagocytosis, and potent cytotoxicity against multiple GPC3-positive HCC cell lines. RNA sequencing and flow cytometry revealed a statistically significant positive correlation between USP22 and the macrophage checkpoint CD24. The addition of the USP22 inhibitor significantly enhanced the tumor-killing capacity of CAR-M in a dose-dependent manner and was associated with reduced CD24 expression on tumor cells. This combinatory strategy robustly suppressed tumor growth in both a murine peritoneal dissemination model and a patient-derived xenograft (PDX) model of HCC. Importantly, the enhanced efficacy was consistently observed across CAR-M cells derived from THP-1, human monocyte-derived macrophages (hMDMs), and human pluripotent stem cells (hPSCs), underscoring its broad applicability. Our findings provide proof-of-concept preclinical evidence supporting further evaluation of combining GPC3 CAR-M therapy with USP22 inhibition as a potential immunotherapeutic strategy for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularCD24 AntigenLiver NeoplasmsMacrophagesGlypicansUbiquitin ThiolesteraseReceptors, Chimeric AntigenHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysDown-RegulationImmunotherapy, AdoptiveGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CD24Chimeric antigen receptor macrophageHepatocellular carcinomaUSP22 inhibition

Substanzen

CD24 AntigenGlypicansUsp22 protein, humanCD24 protein, humanUbiquitin ThiolesteraseGPC3 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • NHC Key Laboratory of Combined Multi-Organ Transplantation, Institute of Organ Transplantation, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, China.
  • School of Clinical Medicine, Hangzhou Medical College, Hangzhou, 311399, China.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Nankai University, Tianjin, 300071, China.

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Medical University
  • Key R&D Plan in Zhejiang Province

Zitieren

APA

Pan, J., Pan, S., Lei, Y., Li, J., Zhong, X., Tang, L., Xu, S., Ling, S., Lu, D., Wang, K., Hao, S., Li, L., Wu, Z., Wang, H., Cheng, T., Shen, J., Xu, X., & Wei, Q. (2026). USP22 inhibition potentiates GPC3 chimeric antigen receptor macrophages efficacy in hepatocellular carcinoma by downregulating tumor CD24 expression. Cancer Letters, 655, 218593. https://doi.org/10.1016/j.canlet.2026.218593

Vancouver

Pan J, Pan S, Lei Y, Li J, Zhong X, Tang L, et al. USP22 inhibition potentiates GPC3 chimeric antigen receptor macrophages efficacy in hepatocellular carcinoma by downregulating tumor CD24 expression. Cancer Letters. 2026;655:218593. doi:10.1016/j.canlet.2026.218593

BibTeX
@article{Pan2026,
  author = {Pan, Jun and Pan, Sheng and Lei, Yunguo and Li, Jinze and Zhong, Xinyang and Tang, Lin and Xu, Shengjun and Ling, Sunbin and Lu, Di and Wang, Kai and Hao, Sha and Li, Li and Wu, Zhonglin and Wang, Haoxuan and Cheng, Tao and Shen, Jun and Xu, Xiao and Wei, Qiang},
  title = {USP22 inhibition potentiates GPC3 chimeric antigen receptor macrophages efficacy in hepatocellular carcinoma by downregulating tumor CD24 expression},
  journal = {Cancer Letters},
  year = {2026},
  volume = {655},
  pages = {218593},
  doi = {10.1016/j.canlet.2026.218593}
}
Kostenlos starten →